Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Kyobu Geka. the Japanese Journal of Thoracic Surgery
|
November 30, 2013
[Excision of the head of the rib]
Yoshifumi Sano, Masayuki Senda
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
June 17, 2004
[Devices for hemofiltration/hemodiafiltration]
Masashi Suzuki, Hajime Hoshino, Masayuki Senda, et al.
Diabetes, Obesity & Metabolism
|
April 4, 2017
Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, et al.
Diabetes, Obesity & Metabolism
|
January 10, 2018
Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS)
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, et al.
Diabetes Research and Clinical Practice
|
December 28, 2020
Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study)
Takahisa Hirose, Masato Odawara, Munehide Matsuhisa, et al.
Diabetes, Obesity & Metabolism
|
March 28, 2017
Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study)
Yuichiro Yamada, Masayuki Senda, Yusuke Naito, et al.
Expert Opinion on Pharmacotherapy
|
August 26, 2020
Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study)
Munehide Matsuhisa, Masato Odawara, Takahisa Hirose, et al.
Expert Opinion on Pharmacotherapy
|
July 23, 2020
Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study)
Masato Odawara, Munehide Matsuhisa, Takahisa Hirose, et al.
Journal of Diabetes Investigation
|
August 8, 2019
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study)
Kohei Kaku, Yusuke Naito, Masayuki Senda, et al.
Journal of Diabetes Investigation
|
April 30, 2019
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Kyobu Geka. the Japanese Journal of Thoracic Surgery
|
November 30, 2013
[Excision of the head of the rib]
Yoshifumi Sano, Masayuki Senda
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
June 17, 2004
[Devices for hemofiltration/hemodiafiltration]
Masashi Suzuki, Hajime Hoshino, Masayuki Senda, et al.
Diabetes, Obesity & Metabolism
|
April 4, 2017
Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, et al.
Diabetes, Obesity & Metabolism
|
January 10, 2018
Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS)
Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, et al.
Diabetes Research and Clinical Practice
|
December 28, 2020
Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study)
Takahisa Hirose, Masato Odawara, Munehide Matsuhisa, et al.
Diabetes, Obesity & Metabolism
|
March 28, 2017
Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study)
Yuichiro Yamada, Masayuki Senda, Yusuke Naito, et al.
Expert Opinion on Pharmacotherapy
|
August 26, 2020
Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study)
Munehide Matsuhisa, Masato Odawara, Takahisa Hirose, et al.
Expert Opinion on Pharmacotherapy
|
July 23, 2020
Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study)
Masato Odawara, Munehide Matsuhisa, Takahisa Hirose, et al.
Journal of Diabetes Investigation
|
August 8, 2019
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study)
Kohei Kaku, Yusuke Naito, Masayuki Senda, et al.
Journal of Diabetes Investigation
|
April 30, 2019
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, et al.
Page
of 2